I agree that new mutational technologies such as gene editing and gain-of-function research call for public debate, global engagement and broad evaluation by experts so that policy-makers are properly informed (see Nature 521, 5; 2015) .
The degree of experimental freedom in research is not the only thing at stake, however. At issue is public trust in the institution of science itself. Similar policy challenges arose when recombinant DNA technology was first developed, which led to safety guidelines being drawn up at the 1975 US Asilomar conference.
An international set of such conferences is now needed to assess the potential risks associated with the latest DNA technologies and to develop a common understanding of where lines should be drawn (see also E. Lanphier et al. Nature 519, 410-411 (2015) and D. Baltimore et al. Science 348, 36-38 (2015) ).
The original Asilomar meeting failed to engage the public in discussions, which we now know is crucial to the regulatory decision-making process. 
Blood-transfusion decisions not simple
We consider that your discussion on the possible overuse of blood transfusions simplifies a complex issue (Nature 520, 24-26; 2015) .
Readers might infer, for example, that a standardized transfusion protocol is safer than individualized bloodmanagement care, or that restricted transfusion in response to a particular haemoglobin concentration is at least as safe and effective as transfusion titrations determined by a range of haemoglobin levels. In fact, neither hypothesis has been tested. As you indicate, physicians need to take into account individuals' primary disease as well as any complications and accompanying disorders. Such factors can improve patient care in the longer term, beyond any simple numerical guidelines for restrictive-transfusion practices.
We have shown that a restrictive-transfusion threshold at 7 grams per decilitre of haemoglobin can be problematic for people with stable blood pressure and cardiovascular status (H. G. Klein and C. Natanson Ann. Intern. Med. 157, 753-754; 2012) . We argue elsewhere that the pivotal trials you cite would have been more robust had they included a range of transfusion triggers, instead of just two arbitrarily selected haemoglobin levels, and a standard-of-care control arm to incorporate all clinical and lab observations for each patient (K. J. Deans et al. Vox Sang. 99, 16-23; 2010 None of these plans will reduce groundwater depletion in the short term. They need to be supported with public education on water use and with integrated water-resource management. Leading local policy-makers and central administration must cooperate to meet the challenge before it is too late. Bobban Subhadra Quorum Innovations, Sarasota, Florida, USA. bbobban@gmail.com 
